Juan Carlos Kaski, new Chief Medical Officer of GlyCardial Diagnostics Blog Post

GlyCardial Diagnostics, based in the Barcelona Science Park, announces the appointment of Prof. Juan Carlos Kaski as Chief Medical Officer. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia.

 

Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma for $10 Million Blog Post

La farmacèutica Aerie Pharmaceuticals, que cotitza al Nasqad, ha annunciat l’adquisició d’Avizorex Pharma (AVX Pharma), amb seu al Parc Científic de Barcelona, per un import de 10 millones de dòlares. La companyia, fundada l’any 2013 com a spin-off de la Universitat Miguel Hernandez de Elche (UMH) per l’emprenedor Patrick Tresserras i el professor Carlos Belmonte de l’Institut de Neurociencias (UMH -CSIC), està especialitzada en el desenvolupament de teràpies innovadores per a la síndrome d’ull sec.

 

GlyCardial begins the clinical trial of its novel diagnostic device for myocardial ischemia Blog Post

GlyCardial Diagnostics, located at the Barcelona Science Park, has announced the enrolment of the first two patients in the EDICA trial: a multicenter international clinical study for the early detection of myocardial ischaemia. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), has developed innovative technology for the detection of Apo J-Glyc protein, as a novel biomarker in blood for the diagnosis and prognosis of myocardial ischemia, and expects to demonstrate the reliability of the new test in hospital laboratories.

 

CataloniaBioHT participates in the Annual Advisory Committee of the Catalonia’s Cluster Programme Blog Post

Last Thursday, the president of CataloniaBio & HealthTech (CataloniaBioHT), Jaume Amat, participated in the Annual Advisory Committee of the Catalonia’s Cluster Programme, promoted by ACCIÓ, alongside the other presidents of the 30 accredited clusters. The association, founded in 2017 as a result of the merger of CataloniaBio and HeathTech Cluster and headquartered in the Barcelona Science Park, has over 160 companies and agents in the field of biomedicine and health. 

 

A Eugin study wins the Clinical Science Award for best clinical poster at ESHRE 2019 Blog Post

The fresh or frozen eggs of the same woman are equally fertile. This is the main conclusion of a study conducted by Eugin Group researchers which won the Clinical Science Award for best clinical poster at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE). The research went head-to-head with 800 other studies, and its principal investigator was David Cornet-Bartolomé, a member of Eugin’s Basic Research Laboratory headquartered in the Barcelona Science Park.

 

The call for the 2019-2020 Research in Society program is open Blog Post

Today, Monday 17 Juny the Barcelona Science Park has kicked off its 19th Research in Society programme with the opening of the pre-registration period for the experimental workshops “Discover research!” and “Do research!”. Places will be allocated to applicant schools in a draw using the list of reservation numbers.

 

The European project GLAM develops a multiplexed biosensor for personalized diagnosis and therapy for bladder cancers Blog Post

A European consortium led by Centre Tecnològic Leitat –through its Biomed Division in the Barcelona Science Park (PCB)– has finished the GLAM project, the aim of which was to develop a photonic biosensor for a non-invasive diagnosis and personalized therapy for bladder cancers. The project involved the participation of 10 European organizations with resources and capabilities from the academia and scientific and business field, among them the Institute for Bioengineering of Catalonia (IBEC), which is also located in PCB.

 

CataloniaBio & HealthTech and Boston MassMEDIC join forces Blog Post

CataloniaBio & HealthTech –the association of companies in the biomedicine and health arena in Catalonia, based in the Barcelona Science Park– and the Massachusetts Medical Device Industry Council (MassMEDIC), the largest association of medical technology companies in the United States, have signed an agreement to foster innovation and collaborations in business and research among their members. 

 

Bionure launches a crowdfunding campaign to fund the preparation the phase 2 study of BN201 Blog Post

Bionure, a biotech company specialized in neuroprotection based in the Barcelona Science Park, has launched a crowdfunding campaign through the Spanish platform of Capital Cell with the objective of raising €1.3M that will be used to finance the preparation of the phase 2 study of its neuroprotectant BN201. The campaign (multiplesmotivos.com) is part of a bridge round of €2.4M that will cover the expenses of regulatory and technical preparation of the phase 2 study.

 

GlyCardial Diagnostics wins the EmprendedorXXI 2019 Award in the ‘Health Tech’ category Blog Post

GlyCardial Diagnostics has won the  the EmprendedorXXI Award in the ‘Health Tech’ category, one of the six awards granted in its twelfth year to recognize those companies in Spain and Portugal with greatest growth potential in several sectors linked to the new innovation trends. The winners have been selected from 961 companies in Spain and Portugal. The biotechnology company, headquartered in the Barcelona Science Park, adds this award to the EmprendedorXXI Award in Catalonia, which it received on 9 May.